title: A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.
abstract: Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.
authors.affiliation: Novartis Vaccines and Diagnostics, Via Fiorentina, 1, 53100 Siena, Italy. elena.fragapane@novartis.com
authors.forename: Elena
authors.initials: E
authors.lastname: Fragapane
authors.forename: Roberto
authors.initials: R
authors.lastname: Gasparini
authors.forename: Francesco
authors.initials: F
authors.lastname: Schioppa
authors.forename: Franco
authors.initials: F
authors.lastname: Laghi-Pasini
authors.forename: Emanuele
authors.initials: E
authors.lastname: Montomoli
authors.forename: Angelika
authors.initials: A
authors.lastname: Banzhoff
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D003429:Cross Reactions; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects / Q000379:methods*; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000008:administration & dosage* / Q000009:adverse effects; D013185:Squalene / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene
references.citation: Clin Infect Dis. 2006 Nov 1;43(9):1135-42
references.pmid: 17029131
references.citation: J Infect Dis. 2009 Jan 15;199(2):184-7
references.pmid: 19067606
references.citation: Vaccine. 2003 Apr 2;21(15):1687-93
references.pmid: 12639491
references.citation: Lancet Infect Dis. 2008 Oct;8(10):650-8
references.pmid: 18922487
references.citation: Lancet. 2001 Jun 16;357(9272):1937-43
references.pmid: 11425416
references.citation: J Infect Dis. 2005 Apr 15;191(8):1210-5
references.pmid: 15776364
references.citation: PLoS One. 2009;4(2):e4384
references.pmid: 19197383
references.citation: Vaccine. 2008 Aug 5;26(33):4160-7
references.pmid: 18599164
references.citation: Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S20-5
references.pmid: 19067611
references.citation: Influenza Other Respir Viruses. 2008 Nov;2(6):243-9
references.pmid: 19453401